Dr Danilov on the Investigation of BTK Degraders in CLL
Alexey Danilov, MD, PhD, discusses the investigation of BTK degraders in the treatment of chronic lymphocytic leukemia.
Future Directions in the Treatment of Mantle Cell Lymphoma
Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.
TRANSCEND FL: Phase 2 Study Results of Lisocabtagene Maraleucel in Patients With R/R Follicular Lymphoma
Alexey Danilov, MD, PhD, reviews data from the phase 2 TRANSCEND FL trial investigating lisocabtagene maraleucel and discusses the clinical implications of the results.
Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma
Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.
Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma
Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Dr Danilov on Treatment Considerations in High-Risk MCL
Alexey Danilov, MD, PhD, discusses considerations for varying treatment approaches in patients with high-risk mantle cell lymphoma.
Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma
Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.
Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma
Experts explain the role of maintenance therapy in mantle cell lymphoma and how it impacts the risk of disease progression.
Dr Danilov on Questions Remaining Across the Treatment Landscape of MCL
Alexey Danilov, MD, PhD, discusses lingering questions that remain across the treatment landscape of mantle cell lymphoma.
Dr Danilov on Therapeutic Options After BTK Inhibitors in MCL
Alexey Danilov, MD, PhD, discusses treatment developments for patients with mantle cell lymphoma who have progressed on BTK inhibitors.
Lisocabtagene Maraleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Primary Analysis of TRANSCEND CLL 004
Alexey Danilov, MD, PhD, presents an analysis of data from the Phase 1 TRANSCEND CLL 004 study investigating lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma
Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.
Overview of Mantle Cell Lymphoma
Kami Maddocks, MD, and Alexey Danilov, MD, PhD, provide an overview of mantle cell lymphoma, including prevalence and common risk factors.
BTK Degraders and Other Targets in Mantle Cell Lymphoma
Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.
The Role of Bispecific Antibodies in Mantle Cell Lymphoma
A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.
Treating Patients With MCL Who Progress on BTK Inhibitors
Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.
CAR T-Cell Therapy in Patients With MCL: Clinical Trial and Real-World Data
A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.
Patient Profile 2: A 60-Year-Old Man With Mantle Cell Lymphoma
Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.
Approaches to Treating Patients With High-Risk Mantle Cell Lymphoma
A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.
Selecting the Appropriate BTKi in MCL and Potential Role of Pirtobrutinib
A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.
BTK Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma
Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.
SHINE Study: Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With MCL
A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.
Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?
Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.
TRIANGLE Study: Ibrutinib vs Stem Cell Transplant in Younger Patients With MCL
Boyu Hu, MD, and Bijal D. Shah, MD, provide their thoughts on the TRIANGLE study looking at ibrutinib versus stem cell transplant in MCL.
Patient Profile 1: A 74-Year-Old Man Diagnosed With Mantle Cell Lymphoma
A patient profile of a 74-year-old man diagnosed with mantle cell lymphoma who receives treatment with a non-covalent BTK inhibitor is presented by Alexey V. Danilov, MD, PhD.
Overview of Mantle Cell Lymphoma and First-Line Treatment Options
Alexey V. Danilov, MD, PhD, provides an overview of the pathophysiology, symptoms, and subtypes of mantle cell lymphoma.
Dr. Danilov on the Differences Between Covalent and Noncovalent BTK Inhibitors in MCL
Alexey V. Danilov, MD, PhD, discusses the key differences between covalent and noncovalent BTK inhibitors in mantle cell lymphoma.
Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLL
Looking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.
Pirtobrutinib and Other Non-Covalent BTK Inhibitors in the Treatment of CLL
The assembled faculty comment on data on the role of non-covalent BTK inhibitors in the CLL treatment landscape, with emphasis on the phase 1/2 BRUIN trial of pirtobrutinib.
Anti-CD20 Regimens and Triplet Therapies in CLL
Orienting the conversation around anti-CD20-drug-based combination and sequencing approaches, the panelists examine key takeaways from the CLL13 and CLL14 clinical trials as well as expectations for real-world data in the future.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512